Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04251416
Recruitment Status : Recruiting
First Posted : January 31, 2020
Last Update Posted : February 27, 2020
Sponsor:
Collaborator:
Immunomedics, Inc.
Information provided by (Responsible Party):
Alessandro Santin, Yale University

Brief Summary:
This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with persistent or recurrent endometrial carcinoma.

Condition or disease Intervention/treatment Phase
Endometrial Carcinoma Drug: Sacituzumab Govitecan Phase 2

Detailed Description:
This is an open-label, Phase 2 study designed to assess the clinical activity of sacituzumab govitecan in subjects with persistent or recurrent endometrial carcinoma with elevated Trop-2 expression.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Evaluation of Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate, in Patients With Persistent or Recurrent Endometrial Carcinoma
Actual Study Start Date : February 25, 2020
Estimated Primary Completion Date : February 2024
Estimated Study Completion Date : February 2026

Arm Intervention/treatment
Experimental: Sacituzumab Govitecan
Sacituzumab govitecan will be administered at 10 mg/kg weekly as an infusion for 2 consecutive weeks (2 weekly doses plus 1 week without treatment represents a single 3 week cycle). Treatment can be continued without a rest period in the absence of progression of disease or unacceptable toxicity.
Drug: Sacituzumab Govitecan
Sacituzumab govitecan will be administered at 10 mg/kg weekly as an infusion for 2 consecutive weeks (2 weekly doses plus 1 week without treatment represents a single 3 week cycle). Treatment can be continued without a rest period in the absence of progression of disease or unacceptable toxicity.
Other Name: IMMU-132




Primary Outcome Measures :
  1. Objective Response Rate (ORR) [ Time Frame: 4 Years ]
    Objective response rate (complete response and partial response rates) by RECIST1.1 criteria in patients with persistent or recurrent endometrial carcinoma (EC)


Secondary Outcome Measures :
  1. Duration of overall survival (OS) [ Time Frame: 6 Years ]
    Overall survival is defined as the duration of time from study entry to death or the date of last contact.

  2. Duration of progression free survival (PFS) [ Time Frame: 6 Years ]
    Progression free survival is defined as the duration of time from study entry to time of progression, death, or is censored at date of last disease assessment

  3. Durable disease control rate (DDCR) [ Time Frame: 6 Years ]
    The percentage of patients who have achieved complete response, partial response, and stable disease

  4. Assess the safety profile of sacituzumab govitecan in endometrial cancer patients (adverse events as assessed by CTCAE v5.0) [ Time Frame: 6 Years ]
    Incidence of treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must have radiologically confirmed (ie, CAT scan and/or MRI) persistent or recurrent EC of epithelial origin that has progressed after prior platinum based chemotherapy or is refractory to platinum-based chemotherapy and has at least 2+ staining for Trop-2.

    • Must have availability of archival tumor tissue FFPE block for TROP-2 testing or newly acquired biopsy (FFPE block) from a metastatic site. Bone biopsies are not allowed.
  • The diagnosis must be histologically confirmed by a gynecologic pathologist.
  • All patients must have measurable disease. Measurable disease is defined as lesions which can be measured by physical examination or by means of medical imaging techniques. Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest dimension to be recorded). Each lesion must be ≥ 20 mm when measured by conventional techniques, including palpation or plain x-ray, or ≥ 10 mm when measured by spiral CT and/or MRI. Ascites and pleural effusions are not to be considered measurable disease.
  • Patients must have at least one "target lesion" to be used to assess response on this protocol as defined by RECIST v1.1. Tumors within a previously irradiated field will be designated as "non-target" lesions unless progression is documented or a biopsy is obtained to confirm persistence following completion of radiation therapy.
  • After undergoing surgery, patients may be optimally or sub optimally debulked.
  • Patients with measurable recurrent disease of any previous substage (I-IV) are eligible to enrollment.
  • Patients must have adequate bone marrow function: WBC greater than or equal to 3,000/ul, Platelets greater than or equal to 75,000/ul, Granulocytes greater than or equal to 1500/ul.
  • Patients must have adequate renal function: creatinine less than or equal to 2.0 mg/dL.
  • Patients must have adequate hepatic function: Bilirubin ≤ 1.5 X laboratory normal. SGOT/SGPT ≤ 3 X laboratory normal or ≤ 5 X laboratory normal if known liver metastases.
  • Patients must have an ECOG performance status of 0 or 1.
  • Patients must have signed an approved informed consent.
  • Patients must be at least 2 weeks beyond prior treatment (chemotherapy, investigational drugs including small molecular inhibitors, endocrine therapy, immunotherapy and/or radiation therapy) or major surgery.
  • Patients must be at least 2 weeks beyond high dose systemic corticosteroids (however, low dose corticosteroids ≤ 20 mg prednisone or equivalent daily are permitted).
  • Patients must have recovered from all acute toxicities to Grade 1 or less from adverse events due to a previously administered agent.

    • Note: Patients with ≤ Grade 2 neuropathy or ≤ Grade 2 alopecia are an exception to this criterion and may qualify for the study
    • Note: If patients received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
  • Patients with recurrent disease may have received multiple prior chemotherapies for treatment of their endometrial cancer.
  • Patients may have received prior immunotherapy therapy alone or in combination with chemotherapy. A 4-week washout period is required between prior immunotherapy treatment and first dose of sacituzumab govitecan.
  • Patients of childbearing potential must have a negative serum pregnancy test within 7 days prior to the study entry and be practicing an effective form of contraception during the study and until conclusion of 12-week post-treatment evaluation period.
  • Patients must be at least 18 years of age.

Exclusion Criteria:

  • Have an active second malignancy. Note: Patients with a history of malignancy that has been completely treated, with no evidence of active cancer for 3 years prior to enrollment, or subjects with surgically-cured tumors with low risk of recurrence are allowed to enroll.
  • Patients with a significant history of cardiac disease within 6 months, i.e., uncontrolled hypertension, unstable angina, uncontrolled congestive heart failure (NYHA classification III-IV) or clinically significant cardiac arrhythmia (other than stable atrial fibrillation) requiring antiarrhythmia therapy.
  • Patients with known history of clinically significant active COPD, or other moderate-to-severe chronic respiratory illness present within 6 months.
  • Patients with any unstable medical issue (including cardiac issues as above, active treatment for symptomatic pulmonary embolism, CVA, renal or hepatic insufficiency, and active infection/sepsis requiring IV antibiotics).
  • Have known active CNS metastases and/or carcinomatous meningitis. Patients with previously treated brain metastases may participate provided they have stable CNS disease for at least 4 weeks prior to the first dose of study drug and all neurologic symptoms have returned to baseline, have no evidence of new or enlarging brain metastases, and are taking ≤ 20 mg/day of prednisone or its equivalent. All patients with carcinomatous meningitis are excluded regardless of clinical stability.
  • Patients who have an uncontrolled seizure disorder, or active neurological disease.
  • Have a known history of HIV-1/2 with uncontrolled viral load and on medications that may interfere with SN-38 metabolism.
  • Have active HBV or HCV. In subjects with a history of HBV or HCV, subjects with a detectable viral load will be excluded.
  • Known hemorrhagic diathesis or active bleeding disorder.
  • Patients with Gilbert's disease.
  • Presence of bulky disease (defined as any single mass >7 cm in its greatest dimension). Patients with a mass over 7 cm, but otherwise eligible, may be considered for enrollment.
  • Patients with active ≥ grade 2 anorexia, nausea or vomiting, diarrhea, and/or signs of intestinal obstruction.
  • Prior history of clinically significant bleeding, intestinal obstruction, or GI perforation within 6 months of initiation of study treatment.
  • Patients with a history of an anaphylactic reaction to irinotecan or ≥ Grade 3 GI toxicity to prior irinotecan.
  • Patients who have previously received topoisomerase I inhibitors.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04251416


Contacts
Layout table for location contacts
Contact: Alessandro D. Santin, M.D. 203-737-4450 alessandro.santin@yale.edu
Contact: Lisa Baker, R.N. 203-785-6398 lisa.baker@yale.edu

Locations
Layout table for location information
United States, Connecticut
Smilow Cancer Hospital at Yale New Haven Recruiting
New Haven, Connecticut, United States, 06510
Contact: Alessandro D. Santin, M.D.    203-737-4450    alessandro.santin@yale.edu   
Contact: Lisa Baker, R.N.    203-785-6398    lisa.baker@yale.edu   
Sponsors and Collaborators
Alessandro Santin
Immunomedics, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Alessandro D. Santin, M.D. Yale University
Layout table for additonal information
Responsible Party: Alessandro Santin, Professor of Obstetrics, Gynecology, and Reproductive Sciences, Yale University
ClinicalTrials.gov Identifier: NCT04251416    
Other Study ID Numbers: 2000026850
First Posted: January 31, 2020    Key Record Dates
Last Update Posted: February 27, 2020
Last Verified: February 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Endometrial Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Diseases